Angel-backed Alpha Cancer Technologies to go public in RTO deal
Bradmer Pharmaceuticals Inc (TSX Venture: BMR.H) has agreed to a reverse take-over transaction with Alpha Cancer Technologies Inc, a Toronto-based pre-clinical biopharmaceutical company with a targeted chemotherapy delivery platform focused on the global oncology market. Upon completion of the transaction, the resulting issuer will carry on the business of Alpha. In Jan. 2013, Alpha secured $2.1 million from XDL Angel Group. The company at the same time received $950,000 from the Federal Economic Development Agency for Southern Ontario to support clinical trials of its chemotherapy platform.
19 February 2014•8 mins read
